MediPharm Labs Corp.. Bolsters Leadership & Operational Expertise to Further Accelerate Growth

MediPharm Labs Corp..

MediPharm Labs Corp. (“MediPharm Labs” or the “Company”-RRB- (TSXV: LABS) continues to build momentum towards its objective of becoming a global leader in pharmaceutical-grade cannabis concentrates, by adding to its existing management strength. MediPharm Labs is very happy to welcome industry veteran David Mayers as rsquo & the Company;s recently appointed leading cannabis compliance professional Anuja Siwakoti as the Company & rsquo, and Chief Operating Officer;s recently appointed Director of Scientific Affairs and Global Regulatory. Both of these senior team members will play critical roles in major rsquo MediPharm Labs & growth plans in Canada and into international markets, where cannabis is legal.

&David ldquo and Anuja reflect the already high degree of professionalism and expertise of our management staff ” states Pat McCutcheon, CEO and President of MediPharm Labs. “Our vision of leadership in cannabis isolates and concentrates requires this standard of qualifications. We continue building strength to meet our targets. ”

David Mayers brings over 28 years of pharmaceutical leadership in large multinational companies and small privately held organizations, with extensive experience in corporate strategy and oversight, research and development (“R&D”-RRB-, quality, lean sigma, production, supply chain, procurement, information technology, finance, product development, product launch, facility expansion, security and the management of controlled substances. Beginning his career as a chemist for SmithKline Beecham (now GlaxoSmithKline), David improved through roles of increasing responsibility for Taro Pharmaceutical Industries Ltd., Merck KGaA, Apotex Inc. and afterwards Purdue Pharma (Canada). Most recently, David served as the Chief Operating Officer and member of the Board of Directors for Impopharma Inc., a pharmaceutical company specializing in the development and launch of pulmonary and nasal inhalation pharmaceutical products. In his role in Impopharma Inc., David led a turn-around of the business ’s R&D programs and eased its acquisition. David received his Hons. B.Sc.

Anuja Siwakoti has 8 years of experience in cannabis work, academia and research in the regulated cannabis industry in Canada. Most recently, Anuja was employed as a Senior Quality/Regulatory Consultant at Cannabis Compliance Inc., global cannabis consulting firm. In that role, she provided quality and regulatory consulting services to over 50 clients, helping with operational gap assessment and GPP/GMP audits, guiding close to one dozen clients with licence reception from Health Canada, and navigating through the cannabis regulatory jurisdiction of multiple countries/US states. Anuja previously worked for two and a half years in Aphria Inc., one of Canada’s major LPs, in a senior role in the Quality Department. She has spoken at numerous conferences and been printed in journals. Anuja holds a Masters degree.

MediPharm Labs has successfully established a team with industry leading expertise in the production of cannabis concentrates. Under the leadership of our recently appointed Chief Operating Officer, David Mayers, and the advice and discipline of our Director of Quality Control and Assurance, Dr. Chris Talpas, MediPharm has developed proprietary methodologies and operational efficiencies which have been leveraged to build a library of purified concentrates and distillates.

The organization ’s production was achieved through the operation of two production shifts run by approximately 20 production technicians. Operations are led by sector specialists with profound expertise in cannabis extraction, complemented by 10+ years of pharmaceutical production expertise to GMP standards. Adjunct cannabis consultants provide additional knowledge from their home markets of California (legal adult-use since Jan 2018 with 150 allowable products) and from the uk with 20+ years chromatophary expertise.

A first-mover in cannabis purification and extraction MediPharm Labs, in Canada has invested in centers that were purpose-built , customized state-of-the-art technologies, proprietary methodologies and an expert team to deliver pharmaceutical-grade and precisely dosable cannabis oils and cannabis concentrates for advanced products. Purified cannabis centers are also the critical components for isolate and have emerged as a basis for ingestion and infused products for both the medical and use markets where globally. MediPharm Labs is in active conversations regarding the importing and exporting of medical cannabis where. Anuja Siwakoti, as the Director of Global Regulatory and Scientific Affairs will assist in advancing MediPharm’s global growth.

Around MediPharm Labs Corp..

MediPharm Labs, through its subsidiary, is a pioneer in the cannabis business and has the distinction of being the first company in Canada to become a certified producer for cannabis oil production under the accessibility to Cannabis for Medical Purposes Regulations (ACMPR) without first getting a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments lab, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to generate pharmaceutical-grade cannabis oil using a competitive edge. MediPharm Labs is concentrated on distillation, secondary extraction methodology, and cannabinoid purification and isolation and research-driven. MediPharm Labs, through its subsidiary, provides Canadian licensed producers and appropriate growers with contract processing of cannabis, providing cannabis oil to qualified businesses for sale. Additionally, MediPharm Labs provides raw materials, formulations, packaging and processing to the creation of ready-to-sell products that are advanced. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also finished its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

For further information, please visit the Company’s website at www.medipharmlabs.com or contact:

Telephone:             705-719-7425 ext. 216
Mail:              investors@medipharmlabs.com

This news release contains “forward-looking information” and “forward-looking statements” (jointly, “forward-looking statements”-RRB- within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any announcement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases like “expects”, or “does not anticipate ”, “is expected”, “expects ” or “does not anticipate”, “aims ”, “budget”, “scheduled”, “predictions ”, “quotes ”, “believes” or “plans ” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “could ” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, future growth and growth objectives. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that might cause the actual results and future events to differ materially from those expressed or implied by these forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to get regulatory approvals. Readers should not place undue reliance on the statements and information. The Company assumes no obligation to update the statements of opinions, beliefs, projections, or other elements, if they change except as required by law.

Published at Fri, 19 Oct 2018 14:46:20 +0000

Posted in: Investing

Comments are closed.